Tumor-associated antigen-specific T-cell activation

"Tumor-associated antigen-specific T-cell activation" is not a single molecule or receptor, but rather describes a biological process in which T cells are activated upon recognizing tumor-associated antigens (TAAs) presented by major histocompatibility complex (MHC) molecules on the surface of tumor cells or antigen-presenting cells. This process involves the engagement of the T cell receptor (TCR) with peptide-MHC complexes, often requiring additional co-stimulatory signals from other receptors. The specificity and effectiveness of this immune response are central to many cancer immunotherapies, including checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies[1][2]. However, "tumor-associated antigen-specific T-cell activation" itself is not a discrete therapeutic target like a protein or enzyme; rather, it refers to an immunological event that can be modulated by targeting various molecular components involved in this pathway—such as specific TAAs, MHC molecules, co-receptors like CD28 or PD-1/PD-L1 axis, and engineered receptors in CAR-T therapy[1][2]. Because this entry does not correspond to a unique molecule/receptor but instead describes an immune mechanism/process involving multiple targets and pathways, it should be flagged as incorrect for use as a canonical target name.